Vaccination with a recombinant saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4316-4325

  Wansley, Elizabeth K ^a   Chakraborty, Mala ^a   Hance, Kenneth W ^a   Bernstein, Michael B ^a   Boehm, Amanda L ^a   Guo, Zhimin ^b   Quick, Deborah ^b   Franzusoff, Alex ^b   Greiner, John W ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Globelmmune Inc

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FUNGUS VACCINE; TUMOR VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SEROLOGY; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VACCINATION; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; METHODOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 48249091314     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0393     Document Type: Article

References (31)

1. Franzusoff A, Duke RC, King TH, Lu Y, Rodell TC. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 2005;5:565-75.
2. Everson G, et al. Interim results from a randomized, double-blind, placebo-controlled phase lb study in subjects with chronic HCV after treatment with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins. In: American Association for the Study of Liver Disease; Boston, MA; 2006.
3. Whiting SH, Cohn A, Morse MA, et al. Treatment of Ras mutation-bearing solid tumor using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a Phase I trial. In: ASCO Gastrointestinal Cancers Symposium; San Francisco, CA; 2006.
4. Stubbs AC, Wilson CC. Recombinant yeast as a vaccine vector for the induction of cytotoxic T- lymphocyte responses. Curr Opin Mol Ther 2002; 4:35-40.
5. Heintel T, Breinig F, Schmitt MJ, Meyerhans A. Extensive MHC class l-restricted CD8 T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med Microbiol 2003;39:279-86.
6. Buentke E, Scheynius A. Dendritic cells and fungi. APMIS 2003;111:789-96.
7. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001;7:625-9.
8. Newman SL, Holly A. Candida albicans is phagocytosed, killed, and processed for antigen presentation by human dendritic cells. Infect Immun 2001;69: 6813-22.
9. Buentke E, Heffler LC, Wallin RP, et al. The allergenic yeast Malassezia furfur induces maturation of human dendritic cells. Clin Exp Allergy 2001;31:1583-93.
10. Bauman SK, Nichols KL, Murphy JW. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol 2000;165:158-67.
11. HallerAA, Lauer GM, KingTH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007;25:1452-63.
12. Barron MA, Blyveis N, Pan SC, Wilson CC. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. J Clin Immunol 2006;26:251-64.
13. Franzusoff A, Volpe AM, Josse D, Pichuantes S, Wolf JR. Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing. J Biol Chem 1995;270:3154-9.
14. Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutationselective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004;64: 5084-8.
15. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058-64.
16. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169-76.
17. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res1999;59:676-83.
18. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998;58:1469-77.
19. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7.
20. Kass E, Parker J, Schlom J, Greiner JW. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 2000;12:960-71.
21. Robbins PF, Kantor JA, Salgaller M, et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res1991;51:3657-62.
22. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44:717-26.
23. Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005; 117:444-55.
24. Thompson RC, Pardoll DM, Jaffee EM, et al. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 1996;19:405-13.
25. Couch M, Saunders JK, O'Malley BW, Jr., Pardoll D, Jaffee E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope 2003;113:1401-5.
26. Bernstein MB, Chakraborty M, Wansley EK, et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 2008;26:509-21.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
28. Lu Y, Bellgrau D, Rodell TC, Cruickshank S, Franzusoff A. Yeast-based immunotherapy and the threshold of EGFR expression for immune recognition against glioma overexpressing self-antigen [abstract]. American Association for Cancer Research Annual Proceedings; 2006.
29. + T-cell repertoire. Cancer Res 2005;65:6443-9.
30. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003;9: 1837-49.
31. Matzinger P. Immunology. Memories are made of this? Nature 1994;369:605-6.